Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (8,129)	$ (6,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	40	35
Amortization of operating lease right-of-use assets	287	239
Share-based compensation expense	110	232
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(851)	(127)
Prepaid clinical trial expenses	647
Accounts payable	259	30
Operating lease liability	(267)	(249)
Accrued expenses and other liabilities	(387)	(20)
Net cash used in operating activities	(8,291)	(6,843)
Cash flows from investing activities:
Purchases of property and equipment	(143)	(18)
Net cash used in investing activities	(143)	(18)
Cash flows from financing activities:
Proceeds from exercise of warrants		8,509
Net cash provided by financing activities		8,509
(Decrease) / Increase in cash and cash equivalents and restricted cash	(8,434)	1,648
Cash, cash equivalents and restricted cash at beginning of period	19,181	19,603
Cash, cash equivalents and restricted cash at end of period	10,747	21,251
Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Property and equipment in accounts payable and accrued expenses	$ 52
Increase in operating right-of-use assets and liabilities related to lease modifications		$ 143